We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Bazarov received B.S. in Biochemistry from Cornell University and Ph.D. in Molecular Biophysics and Biochemistry from Yale. His research in UCSF and Lawrence Berkeley National Laboratory focused on telomerase regulation in breast cancer. Dr. Bazarov is a co-inventor on 17 issued patents. Prior to founding Enlil Therapeutics in 2017, he was a first employee in three startups. He came up with an idea of curative treatment for IPF while still in academia, when attending the Telomere and Telomerase conference back in 2007. However, a lack of animal model and reliable delivery system made the idea difficult to execute for a small company with limited funds and runway. He did, however, follow the field closely for the next ten years. Recent discoveries of new telomere-related IPF models, as well as experience he gained in early stage companies allowed Dr. Bazarov to see a direct path from an idea to a product. Since starting Enlil, he has been working in the company full time.
This speaker's sessions: